CN111154802B - Ecm1基因敲除小鼠在抗肝纤维化药物筛选中的应用 - Google Patents
Ecm1基因敲除小鼠在抗肝纤维化药物筛选中的应用 Download PDFInfo
- Publication number
- CN111154802B CN111154802B CN201811326908.6A CN201811326908A CN111154802B CN 111154802 B CN111154802 B CN 111154802B CN 201811326908 A CN201811326908 A CN 201811326908A CN 111154802 B CN111154802 B CN 111154802B
- Authority
- CN
- China
- Prior art keywords
- ecm1
- liver
- liver fibrosis
- gene
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012216 screening Methods 0.000 title claims abstract description 20
- 101150077445 Ecm1 gene Proteins 0.000 title abstract description 37
- 239000003814 drug Substances 0.000 title abstract description 20
- 238000003209 gene knockout Methods 0.000 title abstract description 18
- 206010019668 Hepatic fibrosis Diseases 0.000 title abstract description 17
- 229940079593 drug Drugs 0.000 title abstract description 12
- 241000699670 Mus sp. Species 0.000 title description 125
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 134
- 101000866526 Homo sapiens Extracellular matrix protein 1 Proteins 0.000 claims abstract description 122
- 102100031758 Extracellular matrix protein 1 Human genes 0.000 claims abstract description 105
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 57
- 201000010099 disease Diseases 0.000 claims abstract description 56
- 210000004027 cell Anatomy 0.000 claims abstract description 51
- 238000010171 animal model Methods 0.000 claims abstract description 41
- 238000012360 testing method Methods 0.000 claims abstract description 36
- 230000000415 inactivating effect Effects 0.000 claims abstract description 8
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 121
- 210000004185 liver Anatomy 0.000 claims description 116
- 238000000034 method Methods 0.000 claims description 55
- 230000014509 gene expression Effects 0.000 claims description 51
- 210000001130 astrocyte Anatomy 0.000 claims description 32
- 230000004913 activation Effects 0.000 claims description 30
- 102000008186 Collagen Human genes 0.000 claims description 27
- 108010035532 Collagen Proteins 0.000 claims description 27
- 229920001436 collagen Polymers 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 20
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 20
- 229960002591 hydroxyproline Drugs 0.000 claims description 20
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 20
- 230000002779 inactivation Effects 0.000 claims description 19
- 229940124606 potential therapeutic agent Drugs 0.000 claims description 17
- 206010016654 Fibrosis Diseases 0.000 claims description 15
- 230000002269 spontaneous effect Effects 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 6
- 108010082126 Alanine transaminase Proteins 0.000 claims description 6
- 230000007882 cirrhosis Effects 0.000 claims description 6
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 4
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims description 4
- 206010072268 Drug-induced liver injury Diseases 0.000 claims description 4
- 230000002222 downregulating effect Effects 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 208000004930 Fatty Liver Diseases 0.000 claims description 3
- 208000027761 Hepatic autoimmune disease Diseases 0.000 claims description 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 3
- 206010019799 Hepatitis viral Diseases 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000003124 biologic agent Substances 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 201000001862 viral hepatitis Diseases 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 210000003995 blood forming stem cell Anatomy 0.000 claims 2
- 238000011813 knockout mouse model Methods 0.000 description 72
- 238000001994 activation Methods 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 241000702421 Dependoparvovirus Species 0.000 description 19
- 241000700605 Viruses Species 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 16
- 238000010186 staining Methods 0.000 description 15
- 102100022337 Integrin alpha-V Human genes 0.000 description 14
- 108010040765 Integrin alphaV Proteins 0.000 description 14
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 13
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 13
- 239000006166 lysate Substances 0.000 description 12
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 11
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 11
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 11
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 11
- 108060001084 Luciferase Proteins 0.000 description 11
- 239000005089 Luciferase Substances 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 101100388632 Mus musculus Ecm1 gene Proteins 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 239000004973 liquid crystal related substance Substances 0.000 description 10
- 206010003445 Ascites Diseases 0.000 description 9
- 210000002744 extracellular matrix Anatomy 0.000 description 9
- 230000004761 fibrosis Effects 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- 210000004738 parenchymal cell Anatomy 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000002440 hepatic effect Effects 0.000 description 8
- 230000006801 homologous recombination Effects 0.000 description 8
- 238000002744 homologous recombination Methods 0.000 description 8
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 7
- 102000006495 integrins Human genes 0.000 description 7
- 108010044426 integrins Proteins 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical class Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 210000001671 embryonic stem cell Anatomy 0.000 description 5
- 238000011532 immunohistochemical staining Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 4
- 102400000401 Latency-associated peptide Human genes 0.000 description 4
- 101800001155 Latency-associated peptide Proteins 0.000 description 4
- 239000012083 RIPA buffer Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000003505 heat denaturation Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 239000012160 loading buffer Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 101710127949 Extracellular matrix protein 1 Proteins 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000049939 Smad3 Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- -1 small molecule compound Chemical class 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- 101150044789 Cap gene Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100036912 Desmin Human genes 0.000 description 2
- 108010044052 Desmin Proteins 0.000 description 2
- 101100388631 Homo sapiens ECM1 gene Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000005045 desmin Anatomy 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 102000054414 human ECM1 Human genes 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000007232 portal hypertension Diseases 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 101150066583 rep gene Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 102000014898 transaminase activity proteins Human genes 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241001428586 Human adenovirus D8 Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101001058230 Mus musculus Gamma-enolase Proteins 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000007374 Smad Proteins Human genes 0.000 description 1
- 108010007945 Smad Proteins Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000001056 activated astrocyte Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 231100000594 drug induced liver disease Toxicity 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011819 knockout animal model Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
- A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/10—Vectors comprising a non-peptidic targeting moiety
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Abstract
Description
Claims (12)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811326908.6A CN111154802B (zh) | 2018-11-08 | 2018-11-08 | Ecm1基因敲除小鼠在抗肝纤维化药物筛选中的应用 |
US17/292,296 US20220095596A1 (en) | 2018-11-08 | 2019-08-27 | Use of ecm1 gene-knockout mouse in screening of anti-hepatic fibrosis drug |
EP19881112.7A EP3878959A4 (en) | 2018-11-08 | 2019-08-27 | USE OF AN ECM1 PRECISE DETECTION MOUSE IN SCREENING ANTI-PULMONARY FIBROSIS AGENTS |
PCT/CN2019/102889 WO2020093760A1 (zh) | 2018-11-08 | 2019-08-27 | Ecm1基因敲除小鼠在抗肝纤维化药物筛选中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811326908.6A CN111154802B (zh) | 2018-11-08 | 2018-11-08 | Ecm1基因敲除小鼠在抗肝纤维化药物筛选中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111154802A CN111154802A (zh) | 2020-05-15 |
CN111154802B true CN111154802B (zh) | 2023-05-02 |
Family
ID=70555139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811326908.6A Active CN111154802B (zh) | 2018-11-08 | 2018-11-08 | Ecm1基因敲除小鼠在抗肝纤维化药物筛选中的应用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220095596A1 (zh) |
EP (1) | EP3878959A4 (zh) |
CN (1) | CN111154802B (zh) |
WO (1) | WO2020093760A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111135311B (zh) * | 2018-11-02 | 2023-06-13 | 中国科学院分子细胞科学卓越创新中心 | Ecm1在预防和/或治疗肝纤维化相关疾病中的应用 |
CN111647656A (zh) * | 2020-05-15 | 2020-09-11 | 华中科技大学同济医学院附属同济医院 | mir-29a基因在检测肝癌及肝纤维化中的应用及所述基因条件敲入小鼠的构建方法 |
CN112961882A (zh) * | 2021-02-26 | 2021-06-15 | 四川大学华西医院 | 一种肝脏纤维化疾病模型的构建方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106946821A (zh) * | 2017-04-01 | 2017-07-14 | 郑州大学 | 穿心莲内酯衍生物及其3,19酯化物在制备抗肝纤维化药物中的应用 |
CN109142738A (zh) * | 2017-06-16 | 2019-01-04 | 中国科学院上海巴斯德研究所 | Ecm1作为血清学检测肝纤维化的标志物及其应用 |
CN111135311A (zh) * | 2018-11-02 | 2020-05-12 | 中国科学院上海生命科学研究院 | Ecm1在预防和/或治疗肝纤维化相关疾病中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552910B (zh) * | 2010-12-31 | 2014-06-04 | 中国科学院上海生命科学研究院 | 细胞外基质蛋白1及其调节剂在制备过敏性疾病诊断或治疗药物中的应用 |
US20130101553A1 (en) * | 2011-04-18 | 2013-04-25 | The Regents Of The University Of California | Inducing inactivation of fibrogenic myofibroblasts |
CN103361336A (zh) * | 2012-03-31 | 2013-10-23 | 上海南方模式生物研究中心 | 雄性生育障碍动物模型及其制法和用途 |
US9134326B2 (en) * | 2013-03-14 | 2015-09-15 | Battelle Memorial Institute | Biomarkers for liver fibrosis |
CN107801691B (zh) * | 2017-12-06 | 2021-06-11 | 凯斯艾生物科技(苏州)有限公司 | 一种非酒精性慢性脂肪性肝炎大鼠模型及其构建方法和用途 |
-
2018
- 2018-11-08 CN CN201811326908.6A patent/CN111154802B/zh active Active
-
2019
- 2019-08-27 US US17/292,296 patent/US20220095596A1/en active Pending
- 2019-08-27 WO PCT/CN2019/102889 patent/WO2020093760A1/zh unknown
- 2019-08-27 EP EP19881112.7A patent/EP3878959A4/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106946821A (zh) * | 2017-04-01 | 2017-07-14 | 郑州大学 | 穿心莲内酯衍生物及其3,19酯化物在制备抗肝纤维化药物中的应用 |
CN109142738A (zh) * | 2017-06-16 | 2019-01-04 | 中国科学院上海巴斯德研究所 | Ecm1作为血清学检测肝纤维化的标志物及其应用 |
CN111135311A (zh) * | 2018-11-02 | 2020-05-12 | 中国科学院上海生命科学研究院 | Ecm1在预防和/或治疗肝纤维化相关疾病中的应用 |
Non-Patent Citations (2)
Title |
---|
Weiguo Fan et al..ECM1 Prevents Activation of Transforming Growth Factor β, Hepatic Stellate Cells, and Fibrogenesis in Mice.《Gastroenterology》.2019,第1-16页. * |
李文定 等.细胞外基质蛋白1在多房棘球蚴感染小鼠肝纤维化过程中的作用.《中国寄生虫学与寄生虫病杂志》.2021,第39卷(第39期),第296-303页. * |
Also Published As
Publication number | Publication date |
---|---|
EP3878959A1 (en) | 2021-09-15 |
US20220095596A1 (en) | 2022-03-31 |
EP3878959A4 (en) | 2022-08-17 |
WO2020093760A1 (zh) | 2020-05-14 |
CN111154802A (zh) | 2020-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Maina et al. | Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development | |
Pazirandeh et al. | Multiple phenotypes in adult mice following inactivation of the Coxsackievirus and Adenovirus Receptor (Car) gene | |
KR101870246B1 (ko) | 신질환의 예방 또는 치료제 | |
JP6143015B2 (ja) | 肝疾患の予防または治療剤 | |
Cooley et al. | Fibulin-1 is required for morphogenesis of neural crest-derived structures | |
CN111154802B (zh) | Ecm1基因敲除小鼠在抗肝纤维化药物筛选中的应用 | |
Inoue et al. | A mouse line expressing Sall1‐driven inducible Cre recombinase in the kidney mesenchyme | |
CA2947899C (en) | Humanized dipeptidyl peptidase iv (dpp4) animals | |
Kallewaard et al. | Tissue-specific deletion of the coxsackievirus and adenovirus receptor protects mice from virus-induced pancreatitis and myocarditis | |
JP5642729B2 (ja) | 線維性疾患のためのモデルとしての遺伝子導入動物 | |
RU2577988C2 (ru) | Муриновая модель воспаления с делецией il33 n-концевого домена | |
JP5250810B2 (ja) | ユートロフィン遺伝子発現増強物質のスクリーニング | |
Ng et al. | Fibroblast-specific IL11 signaling is required for lung fibrosis and inflammation | |
US8603992B2 (en) | Compositions comprising MG29 nucleic acids, polypeptides, and associated methods of use | |
Mourkioti et al. | Analysis of CRE‐mediated recombination driven by myosin light chain 1/3 regulatory elements in embryonic and adult skeletal muscle: A tool to study fiber specification | |
WO2008088694A2 (en) | Regulation of lipid droplet formation by modulation of fit1 and fit2 and uses thereof | |
Cazzin et al. | Adenoviral-mediated Cre expression effectively suppresses GlyT1 binding in the thalamic area of GlyT1 conditional knock-out mice | |
JP2004154135A (ja) | ノックアウト非ヒト動物 | |
WO2004074475A1 (ja) | 転写制御シスエレメント及びそれに特異的に結合する転写調節因子並びにそれらの用途 | |
JP2005187408A (ja) | 血管新生調節剤 | |
US20060123496A1 (en) | Animal models | |
JP2006025647A (ja) | Fsp27ノックアウト動物 | |
JP2004514435A (ja) | 生体代謝の修飾 | |
AU2012233059A1 (en) | Compositions comprising MG29 nucleic acids, polypeptides and associated methods of use | |
JP2006509795A (ja) | インスリンシグナル伝達調節異常と関係する症状の処置方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200518 Address after: 200031 building 35, No. 320, Yueyang Road, Xuhui District, Shanghai Applicant after: Center for excellence and innovation of molecular cell science, Chinese Academy of Sciences Address before: 200031 Yueyang Road, Shanghai, No. 319, No. Applicant before: SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20200515 Assignee: Yingchuang Intelligence (Shanghai) Biotechnology Co.,Ltd. Assignor: Center for excellence and innovation of molecular cell science, Chinese Academy of Sciences Contract record no.: X2024980001852 Denomination of invention: Application of ECM1 gene knockout mice in screening anti liver fibrosis drugs Granted publication date: 20230502 License type: Exclusive License Record date: 20240202 |